Insights on BCEL
Vs NVO
In the last 1 year, Novo Nordisk A/s has given 44.3% return, outperforming this stock by 136.3%
Vs NVO
In the last 3 years, Novo Nordisk A/s has given 242.1% return, outperforming this stock by 341.5%
Highlights
Market Capitalization | 3.2M |
Book Value | $0.27 |
Earnings Per Share (EPS) | -2.5 |
Wall Street Target Price | 5.5 |
Profit Margin | 0.0% |
Operating Margin TTM | 0.0% |
Return On Assets TTM | -51.2% |
Return On Equity TTM | -182.7% |
Revenue TTM | 0.0 |
Revenue Per Share TTM | 0.0 |
Quarterly Revenue Growth YOY | 0.0% |
Gross Profit TTM | 0.0 |
EBITDA | -76.4M |
Diluted Eps TTM | -2.5 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | -2.04 |
EPS Estimate Next Year | -0.86 |
EPS Estimate Current Quarter | -0.38 |
EPS Estimate Next Quarter | -0.35 |
Peers
| Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
|---|---|---|---|---|---|
 Moderna, Inc. | -0.45% | 20.22% | -27.91% | -35.9% | 341.66% |
 Regeneron Pharmaceuticals, Inc. | -6.85% | 6.85% | 9.08% | 78.94% | 160.71% |
 Novo Nordisk A/s | -7.1% | 22.03% | 44.33% | 239.61% | 408.97% |
 Vertex Pharmaceuticals Incorporated | -4.18% | 5.53% | 20.27% | 79.84% | 136.07% |
| Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
|---|---|---|---|---|---|---|---|---|
Moderna, Inc. | 24.73 | NA | 0.0 | -7.21 | -0.29 | -0.12 | NA | 36.27 |
Regeneron Pharmaceuticals, Inc. | 25.84 | 25.84 | 1.46 | 45.15 | 0.16 | 0.08 | NA | 242.47 |
Novo Nordisk A/s | 46.75 | 46.75 | 2.4 | 3.36 | 0.88 | 0.23 | 0.01 | 23.9 |
Vertex Pharmaceuticals Incorporated | 28.57 | 28.57 | 0.53 | 16.72 | 0.23 | 0.13 | NA | 68.22 |
| Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
|---|---|---|---|---|---|
Moderna, Inc. | Buy | $40.3B | 341.66% | 24.73 | -68.84% |
Regeneron Pharmaceuticals, Inc. | Buy | $98.6B | 160.71% | 25.84 | 30.14% |
Novo Nordisk A/s | Buy | $559.8B | 408.97% | 46.75 | 36.03% |
Vertex Pharmaceuticals Incorporated | Buy | $102.7B | 136.07% | 28.57 | 36.68% |
Corporate Announcements
Earnings
’s price-to-earnings ratio stands at None
Read More
